Abstract 1813
Background
Few studies have compared long-term patient reported AEs of men with Prostate Cancer (PCa) treated with dose-escalation by means of BT/RT to RT (70-78 Gy) alone. In this study, we compare AEs and quality of life (QoL) between these two treatment modalities.
Methods
259 eligible men from the BT/RT cohort (2004-2011) and 123 patients (2009-2010) from a RT cohort assessed their AEs and QoL by questionnaires a minimum of 5 years after treatment. Hormonal therapy was given for 1-2 years. EPIC-26 covered urinary, sexual and bowel function and bother. The hormone domain was excluded. The SF-12 questionnaire covered QoL. The scores ranged from 0 (worst) to 100 (best). Clinical significance was set to a score difference > 10 points. Statistical significance was evaluated by Student t-test with significance level p < 0.05. Chronic fatigue was reported as percentage.
Results
Median age at survey was 74 years for both cohorts. The EPIC-26 and SF12 scores for the above domains were similar in the two cohorts with no clinical or statistical significance (Table). Chronic fatigue was higher after treatment with RT compared BT/RT, although not significantly.Table: 853P
| Measure | BT/RT Mean (SD) | RT Mean (SD) | P value |
|---|---|---|---|
| Sexual function | 27.9 (29.5) n = 255 | 20.8 (24.3) n = 120 | 0.06 |
| Sexual bother | 48.2 (37.5) n = 254 | 45.9 (34.7) n = 121 | 0.56 |
| Urinary function | 83.6 (18.0) n = 258 | 80.1 (20.5) n = 123 | 0.10 |
| Urinary irritation/obstruction | 81.3 (19.6) n = 249 | 81.8 (16.8) n = 113 | 0.80 |
| Urinary incontinence | 88.7 (18.1) n = 258 | 85.0 (22.5) n = 123 | 0.11 |
| Urinary bother | 79.9 (26.5) n = 257 | 77.6 (30.0) n = 123 | 0.47 |
| Bowel function | 86.7 (20.6) n = 254 | 83.1 (21.7) n = 121 | 0.12 |
| Bowel bother | 83.0 (25.1) n = 258 | 80.4 (26.7) n = 121 | 0.34 |
| PCS12 (SF12) | 46.4 (10.5) n = 224 | 45.1 (10.1) n = 101 | 0.30 |
| MCS12 (SF12) | 53.6 (8.0) n = 224 | 52.7 (9.2) n = 101 | 0.38 |
| Chronic fatigue | 22.0% n = 199 | 27.1% n = 86 | 0.28 |
Conclusions
Dose-escalation by means of BT/RT does not increase the AEs reported for the urinary, bowel and sexual domains of EPIC-26 or health-related QoL. Hence, BT/RT is a good treatment option for eligible patients.
Clinical trial identification
Legal entity responsible for the study
Wolfgang Lilleby.
Funding
Raagholt Foundation, Bergersen Foundation, Eckbo Foundation.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract